Nav1.7 Modulator Bearing a 3-Hydroxyindole Backbone Holds the Potential to Reverse Neuropathic Pain

Area of Science:

• Neuroscience
• Pharmacology
• Medicinal Chemistry

Background:

• Chronic pain affects over 10% of the global population, with current treatments being insufficient.
• Voltage-gated sodium channels (Navs) are crucial for pain signal transmission and are key targets for nonopioid analgesics.
• Specific Nav subtypes like Nav1.7 in dorsal root ganglion (DRG) neurons are of particular interest for pain relief.

Purpose of the Study:

• To screen dihydrobenzofuran and 3-hydroxyoxindole hybrid molecules as potential Nav inhibitors.
• To evaluate the efficacy of identified compounds in blocking neuronal activity and pain signaling.
• To investigate the specific Nav subtypes targeted by the most potent compound and its mechanism of action.

Main Methods:

• Veratridine (VTD)-based calcium imaging to screen hybrid molecules against Navs.
• Voltage clamp recordings to assess the effects of compound 3g on Na+ currents in DRG neurons.
• Biophysical analysis, selective Nav inhibitors, heterozygous expression systems, and molecular docking to determine target specificity and binding site.

Main Results:

• Compound 3g significantly inhibited VTD-induced neuronal activity and concentration-dependent Na+ currents in DRG neurons.
• 3g demonstrated use-dependent block, slowed Nav activation, and enhanced inactivation.
• 3g preferentially inhibited TTX-sensitive (Nav1.7) over TTX-resistant Na+ currents, binding to VSDIV of Nav1.7.
• Intrathecal administration of 3g reduced mechanical pain behavior in a rat model of nerve injury.

Conclusions:

• Compound 3g is a potent inhibitor of Nav1.7 channels.
• 3g exhibits promising analgesic effects in a preclinical model of chronic pain.
• This molecule represents a potential therapeutic candidate for developing novel nonopioid painkillers.